Sign In
Buy TCON
$0.0322
+0 (+0%)
At Close: Oct 15, 2025
TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma
08:05am, Tuesday, 29'th Jun 2021
Application Included Clinical Trial Data from Soft Tissue Sarcoma Patients Treated with Envafolimab in Phase 1 Trials
TRACON Pharmaceuticals Inc (NASDAQ:TCON) has presented updated data from its Phase 1 study of TJ004309 (uliledlimab) and Tecentriq (atezolizumab) at the American Society of Clinical Oncology (ASCO)
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therape
TRACON Pharmaceuticals says ENVASARC trial to proceed as planned after Independent Data Monitoring Committee recommendation
02:35pm, Tuesday, 01'st Jun 2021
TRACON Pharmaceuticals Inc (NASDAQ:TCON) says the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial will proceed as planned following the review of sa
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
08:05am, Tuesday, 01'st Jun 2021
Trial to Continue as Planned Trial to Continue as Planned
TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
08:05am, Tuesday, 25'th May 2021
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting
08:05am, Thursday, 20'th May 2021
SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q1 2021 Results - Earnings Call Transcript
12:10pm, Thursday, 06'th May 2021
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q1 2021 Results - Earnings Call Transcript
TRACON Pharmaceuticals ends 1Q with $30.4M to fund its cancer drug trials
05:01pm, Wednesday, 05'th May 2021
TRACON Pharmaceuticals Inc (NASDAQ:TCON) ended the first quarter of 2021 on March 31 with cash and equivalents of $30.4 million, which it said will fund its operations into the second half of 2022.
TRACON Pharmaceuticals Announces Appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics
08:05am, Monday, 03'rd May 2021
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON to Report First Quarter 2021 Financial Results and Company Highlights on May 5, 2021
08:05am, Wednesday, 28'th Apr 2021
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty
TRACON Pharmaceuticals driving the development of targeted therapies for cancer via collaborations
01:39pm, Thursday, 25'th Mar 2021
Clinical-stage pipeline includes envafolimab to treat soft-tissue sarcoma Awarded Orphan Drug designation for TRC102 to treat brain and spinal cord cancers Looking for partnerships to help with regul
TRACON Pharmaceuticals Announces Poster Presentation at the 2021 AACR Virtual Annual Meeting
08:05am, Tuesday, 23'rd Mar 2021
Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma
TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference
08:05am, Tuesday, 09'th Mar 2021
SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance
